Elanco Animal Health Logo
US28414H1032
A2N6BH
ELAN

Elanco Animal Health

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 24,26 (+21,91%). A mediana é € 24,26 (+21,91%).

Comprar
  15
Manter
  4
Vender
  2

  • Fitch upgrades Elanco after debt reduction and market share gains

    Fitch Ratings has raised Elanco’s long-term issuer default rating from BB to BB+ and upgraded the rating on senior secured obligations to BBB-, with a stable outlook. The agency cites successful debt reductions of about $650 million since 2024, market share gains in the pet health segment, a broad product portfolio and improved cash‑flow generation. Fitch expects leverage to fall (gross leverage toward 3.0x by end‑2027), rising free cash flows through 2028 and EBITDA margins of around 21–22% after 2026. In the near term, freed cash flow is expected to be used primarily for debt repayment, while Elanco invests in product expansion, manufacturing and targeted acquisitions. » Mais em de.investing.com


  • Elanco receives FDA emergency approval for wound spray CLiK Extra against screw-worm fly

    Elanco has received emergency approval from the FDA for the wound spray CLiK Extra, authorized to prevent infestations by the New World screw-worm fly in livestock and certain wild animals. The topical dicyclanil suspension may be used on sheep, cattle, goats, swine, camelids, captive deer, American bison, bighorn sheep and pronghorn, but it does not treat active infestations. Animals of the listed species must not be slaughtered for human consumption within 86 days after treatment; there is no established milk withdrawal period, and the product must not be used on milk-producing animals for human consumption. CLiK Extra will be available through usual veterinary distribution channels and the approval is valid for the duration of the federal emergency. » Mais em de.investing.com


  • Elanco: study shows Credelio Quattro kills black-legged ticks faster than competitors

    Data in Parasites & Vectors show that Credelio Quattro reduces infections with black-legged ticks within 8 hours after treatment, both on day 0 and on day 28 of the dosing interval. Competing products Simparica Trio and NexGard Plus achieved significant reductions only after 12 and 24 hours, respectively, on day 28. Credelio Quattro is FDA-approved for Lyme prevention in dogs; common side effects in studies were vomiting and diarrhea, and the drug class has been linked to neurological effects. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Elanco Animal Health registou receitas de € 1,2 bi e um ganho líquido de € 47,32 mi
(EUR) junho de 2026
YoY
Receitas 1,2 bi 13,84%
Ganho bruto 699,22 mi 42,83%
Ganho líquido 47,32 mi 406,99%
EBITDA 240,08 mi 7,19%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 10,02 bi
Número de ações
499,45 mi
Máximo/mínimo de 52 semanas
€ 24,24 - € 15,78
Dividendos Não
Beta
1,68
PER (PE Ratio)
-56,49
PEG (PEG Ratio)
0,36
P/VC (PB Ratio)
1,76
P/V (PS Ratio)
2,30

Perfil da empresa

Elanco Animal Health Incorporated, ein Unternehmen für Tiergesundheit, entwickelt, produziert und vermarktet Produkte für Haus- und Nutztiere. Das Unternehmen bietet Produkte zur Vorbeugung von Krankheiten bei Haustieren an, wie z. B. Parasitizide und Impfstoffe zum Schutz von Haustieren vor Würmern, Flöhen und Zecken unter den Marken Seresto, Advantage, Advantix und Advocate; Therapeutika für Haustiere zur Behandlung von Schmerzen, Osteoarthritis, Ohrinfektionen, Herz-Kreislauf-Erkrankungen und dermatologischen Indikationen bei Hunden und Katzen unter den Marken Galliprant und Claro; Impfstoffe, Antibiotika, Parasitizide und andere Produkte für den Einsatz in der Geflügel- und Aquakulturproduktion sowie Produkte für die gesunde Ernährung, einschließlich Enzyme, Probiotika und Präbiotika; und eine Reihe von Impfstoffen, Antibiotika, Implantaten, Parasitiziden und anderen Produkten für die Wiederkäuer- und Schweineproduktion unter den Marken Rumensin und Baytril. Das Unternehmen vertreibt seine Produkte an Drittanbieter, Tierärzte und Nutztierhalter, darunter Rinder- und Milchviehhalter sowie Schweine-, Geflügel- und Aquakulturbetriebe. Elanco Animal Health Incorporated wurde 1954 gegründet und hat seinen Hauptsitz in Greenfield, Indiana.

Nome
Elanco Animal Health
CEO
Jeffrey N. Simmons
Sede Indianapolis, in
EUA
Site
Setor
Cuidados de saúde
Indústria
Produtos farmacêuticos
Entrada em bolsa
20/09/2018
Colaboradores 9.650

Símbolos de ticker

Bolsa Símbolo
NYSE
ELAN
Frankfurt
5EA.F
Düsseldorf
5EA.DU
München
5EA.MU
🍪

Parqet  utiliza cookies. Saber mais